Sometimes, in genetics, two wrongs do make a right. A research team has recently shown that two harmful genetic variants, ...

CAMBRIDGE, Mass., Jun 28, 2012 --- Adverse events were similar between treatment and placebo groups; most events were mild to moderate - --- Pivotal program to evaluate VX-809 (600mg) in combination ...

A phase three clinical trial that UT Southwestern participated in determined that a three-drug combination improved lung function and reduced symptoms in cystic fibrosis (CF) patients who have a ...

This was a prospective, randomized, open-label, blinded end point (PROBE), 30 parallel group study with two treatment arms. A total of 160 outpatients aged 61–75 years entered a 2-week wash-out period ...

Sildenafil is an orally active selective type 5 phosphodiesterase (PDE) inhibitor, and has proven to be an effective agent for the treatment of male ED. Sildenafil inhibits the breakdown of ...

COYA 303 is an investigational biologic combination of COYA 301, Coya’s low-dose interleukin 2 (LD IL-2) and a GLP-1 receptor agonist (GLP-1RA), designed to deliver a multi-targeted immunomodulatory ...